Aesther Healthcare Acquisition registered to offer 10 million units at $10 each. A unit consists of one share of Class A common stock and one-half of one redeemable warrant.
Aesther will target companies in the pharmaceuticals sector.
The new SPAC is led by Chairman and CEO Suren Ajjarapu, who has also served as chairman, CEO and Secretary of TRxADE Health, formerly Trxade Group.
EF Hutton is sole book-runner for the offering. The underwriters have an over-allotment option to purchase up to an additional 1.5 million units.
The SPAC has applied to list on the Nasdaq but has not yet selected a ticker symbol. Read more.
